SAL0137 / Shenzhen Salubris - LARVOL DELTA

SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a) (clinicaltrials.gov) - P1 | N=144 | Active, not recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P1 trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P2 trial • Cardiovascular